Keros Therapeutics, Inc. (NASDAQ:KROS) Short Interest Up 9.4% in March

Keros Therapeutics, Inc. (NASDAQ:KROS) saw a large increase in short interest during the month of March. As of March 31st, there was short interest totalling 2,100,000 shares, an increase of 9.4% from the March 15th total of 1,920,000 shares. Based on an average daily trading volume, of 413,400 shares, the days-to-cover ratio is currently 5.1 days.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on KROS. William Blair reissued an “outperform” rating on shares of Keros Therapeutics in a research note on Wednesday, February 21st. Piper Sandler reissued an “overweight” rating and issued a $105.00 price objective on shares of Keros Therapeutics in a research note on Wednesday, March 27th. Wedbush reissued an “outperform” rating and issued a $86.00 price objective on shares of Keros Therapeutics in a research note on Thursday, February 29th. Truist Financial reaffirmed a “buy” rating and set a $100.00 price target on shares of Keros Therapeutics in a research note on Wednesday, March 13th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $100.00 price target on shares of Keros Therapeutics in a research note on Friday, March 1st. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $86.00.

Keros Therapeutics Price Performance

Keros Therapeutics stock opened at $58.00 on Wednesday. The stock has a market capitalization of $2.09 billion, a P/E ratio of -11.15 and a beta of 1.26. Keros Therapeutics has a 12-month low of $27.02 and a 12-month high of $73.00. The firm’s 50-day moving average is $63.41 and its two-hundred day moving average is $46.63.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings data on Friday, March 1st. The company reported ($1.34) earnings per share for the quarter, topping the consensus estimate of ($1.37) by $0.03. The company had revenue of $0.14 million for the quarter. During the same quarter in the prior year, the firm posted ($1.09) EPS. As a group, analysts forecast that Keros Therapeutics will post -5.11 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Virtus ETF Advisers LLC lifted its holdings in shares of Keros Therapeutics by 7.1% during the 4th quarter. Virtus ETF Advisers LLC now owns 2,743 shares of the company’s stock worth $109,000 after acquiring an additional 182 shares during the period. Wellington Management Group LLP lifted its holdings in shares of Keros Therapeutics by 1.2% during the 1st quarter. Wellington Management Group LLP now owns 18,984 shares of the company’s stock worth $1,032,000 after acquiring an additional 227 shares during the period. California State Teachers Retirement System lifted its holdings in shares of Keros Therapeutics by 1.9% during the 3rd quarter. California State Teachers Retirement System now owns 19,511 shares of the company’s stock worth $734,000 after acquiring an additional 364 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its holdings in Keros Therapeutics by 3.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,898 shares of the company’s stock valued at $513,000 after buying an additional 404 shares during the period. Finally, Amalgamated Bank raised its holdings in Keros Therapeutics by 15.6% in the fourth quarter. Amalgamated Bank now owns 3,245 shares of the company’s stock valued at $156,000 after buying an additional 439 shares during the period. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.